Project Grant R43GM116343

The National Cancer Institute awarded a $1,320,861 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to GE Medical Systems Information Technologies, Inc. (doing business as GE Healthcare Technology & Innovation Center) to establish a simplified and accessible procedure for multi-analyte simultaneous extraction of DNA, RNA, and protein from tumor touch imprints. The objective is to democratize biobanking for low-resource institutes by leveraging tumor touch imprints on...

Partillion Bioscience Corp. was awarded a $659,037 Project Grant from the National Institutes of Health's National Institute of General Medical Sciences to develop reagent products enabling high-throughput screening and selection of single cells based on secreted bio-products. Under the Biomedical Research and Research Training program (CFDA 93.859), Partillion plans to transition its lab-on-a-particle technology—highlighted as a 2020 SLAS Innovation Award winner—into the first reagent product...

The National Institute of General Medical Sciences (NIGMS) awarded a $700,000 Project Grant under the Biomedical Research and Research Training (CFDA 93.859) program to Mirimus, Inc., a self-certified small disadvantaged business located in Brooklyn, NY. The grant funding, with a period of performance from September 20, 2024 to April 19, 2025, will support the creation of next-generation RNA interference (RNAi) therapeutics and the development of an in vivo mouse model to evaluate their efficacy...

The federal Project Grant award of $673,600.00 from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) aims to develop an RNA-based sensor that can detect changes in both mRNA and miRNA within living cells and mouse models. The objective is to create a programmable, synthetic biology tool that can identify diseased cells based on their RNA profiles and trigger...

This Cooperative Agreement award from the National Institutes of Health (NIH) Trans-NIH Research Support program (CFDA 93.310) provides $533,384 to Chromologic LLC to validate a miRNA-based predictive assay for radiation-induced lung injury. The project aims to: (I) validate the performance of the MIDOS assay in a larger patient population; (II) assess the impact of cancer on baseline miRNA levels; (III) evaluate the longitudinal dynamics of miRNA abundance following radiation treatment; (IV)...

This $312,371 Project Grant award from the National Heart Lung and Blood Institute (CFDA #93.837 Cardiovascular Diseases Research) to Biochip Labs Inc., a small business based in Cleveland, Ohio, aims to support the manufacturing and analytical validation of the Microfluidic Impedance Red Cell Assay (MIRCA) for commercial viability. The MIRCA is an in vitro diagnostic technology that measures cellular obstruction in microcapillary networks due to abnormal red blood cell (RBC) deformability...

This federal Project Grant award from the National Center for Advancing Translational Sciences (NCATS) under CFDA 93.350 provides $406,500.00 to Syntr Health Technologies, Inc. to develop an automated, microfluidic tissue dissociation platform called the SYNTRFUGE. This device aims to rapidly and efficiently process solid tumor tissue samples into single cells for diagnostic analysis and research, addressing a critical barrier to more widespread use of single-cell analysis in oncology. The...

This federal Project Grant award of $418,176 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports the development and validation of a novel approach called "Programmable Nucleic Acid Cytometry" at the Sloan-Kettering Institute for Cancer Research. The project aims to advance this innovative method for profiling rare cell populations from tumors and tissues, which offers advantages over traditional antibody-based cell isolation techniques. The work will...

This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $729,703 to The Trustees of Columbia University in the City of New York to develop a technology called "NanoVials" to sort and enrich mesenchymal stem cells (MSCs) based on their extracellular vesicle (EV) secretion levels. The goal is to optimize stem cell therapies for ischemic diseases like myocardial infarction by identifying and utilizing MSCs with...

This $306,509 federal Project Grant awarded by the National Institute on Aging (CFDA 93.866 - Aging Research) to Captis Diagnostics Inc. aims to develop a technology platform for rapid magnetic isolation of neuronal extracellular vesicles (EVs) from blood plasma samples. The goal is to enable the detection of biomarkers for neurological diseases such as Alzheimer's, Parkinson's, and traumatic brain injury through a minimally invasive liquid biopsy approach. Key activities include developing...